Introduction
Protein-energy malnutrition (PEM) is a well-known clinical manifestation of advanced cirrhosis [1, 2] . It is characterized by reduced serum albumin level (visceral protein) and by decreased skeletal muscle volume (muscular protein), with a reported incidence as high as 65-90%, depending on the etiology of disease (alcoholic or nonalcoholic) and the severity of liver failure. PEM is caused by several factors, variably associated in individual patients. A catabolic state, associated with hyperglucagonemia, and an increased calorie/amino acid need to achieve nitrogen balance, contribute to increase the disparity with food intake, frequently reduced by anorexia. PEM largely affects patients' outcome, by increasing the risk of life-threatening complications, which in turn reduce survival and quality of life [3] . Long-term prognosis after liver transplantation also depends on patients' nutritional status.
The ability of branched-chain amino acids (BCAAs) to regulate protein turnover, coupled with their competitive action on amino acid transport across the blood-brain barrier and, ultimately, on the brain synthesis of neurotransmitters, has been the basis for their administration to improve nutrition and to treat hepatic encephalopathy in cirrhosis. Plasma BCAA levels are lower than normal in cirrhosis, further supporting the need for BCAA supplementation.
In the last 25 years several controlled studies addressed the clinical usefulness of BCAA supply in cirrhosis, with conflicting results. In the last 2 years a few studies have contributed further to clarify the role of BCAAs in liver disease.
Branched-chain amino acids in the treatment of advanced cirrhosis A few systematic revisions or meta-analyses on intravenous and oral BCAA treatment are available [4, 5] , but a comprehensive Cochrane review has thrown further light in this area. Als-Nielsen et al. [6 • • ] analyzed 11 randomized trials (556 patients) in which BCAA supplementation was compared with carbohydrates, neomicyne/lactulose and isonitrogenous regimes. Trials of acute hepatic encephalopathy used parenteral administration of pure BCAA (one trial) or BCAA-enriched amino-acid solutions (six trials). Trials of chronic or minimal hepatic encephalopathy used enteral administration of pure BCAA (three trials) or BCAA-enriched diet (one trial). The median amount of BCAA was 28 g/d (range 11 to 57 g) and the median duration of treatment was 7 days (range 4 to 90). The control therapy was glucose (one trial), isonitrogenous control supply (four trials), neomycine or lactulose (five trials), or placebo (one trial). In all trials the administration of BCAAs was accompanied by special nutritive regimens, which were different from trial to trial, but were given to both the experimental and the control group. In 10 trials an additional therapy, namely potassium and electrolytes, diuretics, blood transfusion, insulin, vitamins, and antibiotics, was administered.
Compared with the control administration, BCAAs significantly increased the number of patients improving from hepatic encephalopathy at the end of the treatment (59% vs. 41%; risk ratio, 1.31; 95% confidence limits, 1.04-1.66), but the study did not find any convincing evidence for an effect of BCAAs on survival or adverse events. BCAAs were more effective when given enterally to subjects with chronic encephalopathy, than when given intravenously to patients with acute encephalopathy, in keeping with a possible action through improved nutrition. However, the authors remarked that the trials performed in this field were small, with short follow-up, and most had a low methodological quality [ 
The usefulness of BCAAs in advanced cirrhosis has received further support since the publication of a multicenter, randomized study comparing long-term BCAA supplementation with equicaloric (maltodextrine) or equicaloric/equinitrogenous supplements (lactoalbumin) for one year [7 • • ]. The study enrolled 174 patients with advanced cirrhosis (Child-Pugh score $ 7); exclusion criteria were active alcohol consumption, overt hepatic encephalopathy, refractory ascites, reduced renal function, ChildPugh score $ 12, and suspected hepatocelluar carcinoma. Patients already on a waiting list or being considered for liver transplantation were also excluded, as their followup was likely to be interrupted before the study end.
Primary outcomes were prevention of liver cell failure (death or deterioration to exclusion criteria), need for hospital admission and duration of hospital stay. Secondary outcomes were nutritional parameters, laboratory data and Child-Pugh score, anorexia and health-related quality of life, and need for therapy. Treatment with BCAA significantly reduced the combined event rates (death or progression to liver failure) compared with lactoalbumin (odds ratio, 0.43; 95% confidence interval, 0.19-0.96; P = 0.039) and nonsignificantly compared with maltodexrins (odds ratio, 0.51; 95% confidence interval, 0.23-1.17; P = 0.039)( Table 1 ). The average hospital admission rate was lower in the BCAA arm, compared with control treatments (P = 0.006 and P = 0.003, respectively). In patients who remained in the study, nutritional parameters and liver function tests were, on average, stable or improved during BCAA treatment, and the Child-Pugh score decreased (P = 0.013). Also anorexia and health-related quality of life (Short Form-36 questionnaire) improved.
In summary, this study indicates that in advanced cirrhosis BCAA supplements are better than equicaloric, equinitrogenous supplements with regard to prevention of liver failure and death. The improvement in anorexia and perceived health status deserves special attention. Anorexia is common in cirrhosis [8] , and worsens malnutrition [9] . Health-related quality of life is a relevant outcome in chronic diseases, and is specifically considered by regulatory agencies in the assessment of the utility of new drugs [10] .
Protein malnutrition is responsible for a major incidence of bacterial infection, namely bacteremia and spontaneous bacterial peritonitis. Cirrhotic patients have impaired immune defenses, characterized by a defective phagocytic activity and intracellular killing activity [11] . The incidence of bacterial infections in cirrhotic patients is nearly 4 times greater than that of general hospital population and 42% of these infections are severe [12] . Neutrophils represent the first line of host resistance against bacterial infection, as part of the inflammatory-immune defense mechanism or innate immunity. Nakamura et al. studied the effect of BCAA supplementation on phagocytic function of neutrophils and natural killer activity of lymphocytes in patients with decompensated liver cirrhosis [13 • ]. Five patients received 12 g of BCAA daily for 3 months. The phagocytic function of neutrophils, measured before and at the end of treatment, improved significantly, whereas the improvement in lymphocyte activity, observed in 4 to 5 patients, was not statistically different. In conclusion, BCAA supplementation seems to restore the immune defenses in decompensated liver cirrhosis and it may prevent and reduce the risk of life-threatening infections.
Timing of BCAA supplementation
Late-evening [14] or nocturnal energy supplementation [15] was shown to improve nitrogen balance and abnormal fuel metabolism in patients with cirrhosis, preventing the catabolic losses favored by accelerated fasting [16] . Carbohydrates could be the first choice as energy substrates, but most patients suffer from hyperglycemia. Fukushima et al. compared the effect of daytime versus nocturnal BCAA administration on protein metabolism of cirrhotic patients in 12 cirrhotic patients in a short-term cross-over study [17 • ]. Patients were administered either conventional daytime BCAA granules (4 g BCAAs TID at meals) or nocturnal BCAA (4 g BCAAs at breakfast and 8 g at bedtime) for a week. Another 12 patients, who showed no improvement with previous daytime BCAA administration, were randomly assigned either a nocturnal or a daytime longterm (3 months) BCAA administration. Short-term nocturnal BCAAs significantly improved serum albumin compared with daytime administration. In the long term, nocturnal BCAAs improved serum albumin in cirrhotic patients who had no improvement in serum albumin level with daytime BCAAs, suggesting that nocturnal BCAAs may facilitate albumin synthesis. In conclusion, BCAAs exert a much stronger protein-sparing and anabolic effect when administered at night.
BCAA supplements in hepatocellular carcinoma
In patients with inoperable liver carcinoma, chemoembolization is widely used to prolong survival. Most patients suffer from a tumour-induced increased protein catabolism, adding to malnutrition of cirrhosis. Nutritional support may play an important role in the management of these patients. In a controlled study [18 • ], 88 patients undergoing chemoembolization for hepatocellular carcinoma were randomized to either a treatment group (BCAAenriched formula; 3.2 g valine, 4.0 g leucine and 3.8 g isoleucine) or to a control group for one year. BCAA administration reduced morbidity rate (17.1% vs. 37.2%, P = 0.039). In particular, the BCAA group had lower rates of ascites (7.3% vs. 23.2%, P = 0.043) and peripheral edema (9.8% vs. 27.9%, P = 0.034), and quality of life improved. However, no significant differences in survival were observed in these high-risk patients.
BCAA in liver transplantation
Protein catabolism and the hypermetabolic state significantly affect the prognosis of the patient after orthotopic liver transplantation. Even if the impaired amino acid turnover seems to normalize after liver transplantation [19] , most studies have only been performed in the early postoperative period, in a situation before stable graft function is established. Tietge et al. measured circulating levels and hepatic turnover of amino acids in patients with end-stage liver disease and in the long-term course after successful liver transplantation [20] . BCAA levels increased, but failed to normalize more than 6 months after transplantation. The study demonstrates persistent changes in amino acid metabolism of cirrhosis, which are not fully normalized by transplantation.
Mechanism for BCAA effectiveness in advanced cirrhosis
The beneficial effects of BCAAs in varied liver diseases raised questions as to the mechanism of improved liver function. The therapeutic effect of BCAA supplementation is likely to derive from increased availability of substrates for protein synthesis in liver parenchyma. In experimental animals and humans liver resection stimulates a regenerative response, mediated by circulating factors, including hepatocyte growth factor (HGF), a pleiotropic substance with mitogenic activity [21] . BCAAs, namely leucine, are a potent stimulator of HGF secretion by hepatic stellate cells [22] . Accordingly, the prevention of liver failure observed in patients with advanced cirrhosis during BCAA supplementation might stem from increased liver regeneration, compensating for progressive liver cell death.
Conclusion
After more than 25 years, there is no consensus on the usefulness of BCAA for treatment of advanced cirrhosis to improve nutritional status and to prevent encephalopathy. The large study published in 2003 [7 • • ], 'the mother of all BCAA supplement studies' as named in an editorial published in the journal, Gastroenterology, has been criticized [23 • ], both scientifically and on the basis of economic considerations. Patients intolerant to dietary proteins are probably a minority of cirrhotic patients [24] , but this treatment is the only way to prevent catabolic losses and improve prognosis in this specific clinical setting.
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